Abstract
A retrospective, international, multicenter study was undertaken to assess: (i) the prognostic role of 'interim' positron emission tomography performed during treatment with doxorubicin, bleomycin, vinblastine and dacarbazine in patients with Hodgkin lymphoma; and (ii) the reproducibility of the Deauville five-point scale for the interpretation of interim positron emission tomography scan. Two hundred and sixty patients with newly diagnosed Hodgkin lymphoma were enrolled. Fifty-three patients with early unfavorable and 207 with advanced-stage disease were treated with doxorubicin, bleomycin, vinblastine and dacarbazine ± involved-field or consolidation radiotherapy. Positron emission tomography scan was performed at baseline and after two cycles of chemotherapy. Treatment was not changed according to the results of the interim scan. An international panel of six expert reviewers independently reported the scans using the Deauville five-point scale, blinded to treatment outcome. Forty-five scans were scored as positive (17.3%) and 215 (82.7%) as negative. After a median follow up of 37.0 (2-110) months, 252 patients are alive and eight have died. The 3-year progression-free survival rate was 83% for the whole study population, 28% for patients with interim positive scans and 95% for patients with interim negative scans (P
| Original language | English |
|---|---|
| Pages (from-to) | 1107-1113 |
| Number of pages | 7 |
| Journal | Haematologica |
| Volume | 99 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - Jun 1 2014 |
Fingerprint
ASJC Scopus subject areas
- Hematology
- Medicine(all)
Cite this
The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale. / Gallamini, Andrea; Barrington, Sally F.; Biggi, Alberto; Chauvie, Stephane; Kostakoglu, Lale; Gregianin, Michele; Meignan, Michel; Mikhaeel, George N.; Loft, Annika; Zaucha, Jan M.; Seymour, John F.; Hofman, Michael S.; Rigacci, Luigi; Pulsoni, Alessandro; Coleman, Morton; Dann, Eldad J.; Trentin, Livio; Casasnovas, Olivier; Rusconi, Chiara; Brice, Pauline; Bolis, Silvia; Viviani, Simonetta; Salvi, Flavia; Luminari, Stefano; Hutchings, Martin.
In: Haematologica, Vol. 99, No. 6, 01.06.2014, p. 1107-1113.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale
AU - Gallamini, Andrea
AU - Barrington, Sally F.
AU - Biggi, Alberto
AU - Chauvie, Stephane
AU - Kostakoglu, Lale
AU - Gregianin, Michele
AU - Meignan, Michel
AU - Mikhaeel, George N.
AU - Loft, Annika
AU - Zaucha, Jan M.
AU - Seymour, John F.
AU - Hofman, Michael S.
AU - Rigacci, Luigi
AU - Pulsoni, Alessandro
AU - Coleman, Morton
AU - Dann, Eldad J.
AU - Trentin, Livio
AU - Casasnovas, Olivier
AU - Rusconi, Chiara
AU - Brice, Pauline
AU - Bolis, Silvia
AU - Viviani, Simonetta
AU - Salvi, Flavia
AU - Luminari, Stefano
AU - Hutchings, Martin
PY - 2014/6/1
Y1 - 2014/6/1
N2 - A retrospective, international, multicenter study was undertaken to assess: (i) the prognostic role of 'interim' positron emission tomography performed during treatment with doxorubicin, bleomycin, vinblastine and dacarbazine in patients with Hodgkin lymphoma; and (ii) the reproducibility of the Deauville five-point scale for the interpretation of interim positron emission tomography scan. Two hundred and sixty patients with newly diagnosed Hodgkin lymphoma were enrolled. Fifty-three patients with early unfavorable and 207 with advanced-stage disease were treated with doxorubicin, bleomycin, vinblastine and dacarbazine ± involved-field or consolidation radiotherapy. Positron emission tomography scan was performed at baseline and after two cycles of chemotherapy. Treatment was not changed according to the results of the interim scan. An international panel of six expert reviewers independently reported the scans using the Deauville five-point scale, blinded to treatment outcome. Forty-five scans were scored as positive (17.3%) and 215 (82.7%) as negative. After a median follow up of 37.0 (2-110) months, 252 patients are alive and eight have died. The 3-year progression-free survival rate was 83% for the whole study population, 28% for patients with interim positive scans and 95% for patients with interim negative scans (P
AB - A retrospective, international, multicenter study was undertaken to assess: (i) the prognostic role of 'interim' positron emission tomography performed during treatment with doxorubicin, bleomycin, vinblastine and dacarbazine in patients with Hodgkin lymphoma; and (ii) the reproducibility of the Deauville five-point scale for the interpretation of interim positron emission tomography scan. Two hundred and sixty patients with newly diagnosed Hodgkin lymphoma were enrolled. Fifty-three patients with early unfavorable and 207 with advanced-stage disease were treated with doxorubicin, bleomycin, vinblastine and dacarbazine ± involved-field or consolidation radiotherapy. Positron emission tomography scan was performed at baseline and after two cycles of chemotherapy. Treatment was not changed according to the results of the interim scan. An international panel of six expert reviewers independently reported the scans using the Deauville five-point scale, blinded to treatment outcome. Forty-five scans were scored as positive (17.3%) and 215 (82.7%) as negative. After a median follow up of 37.0 (2-110) months, 252 patients are alive and eight have died. The 3-year progression-free survival rate was 83% for the whole study population, 28% for patients with interim positive scans and 95% for patients with interim negative scans (P
UR - http://www.scopus.com/inward/record.url?scp=84901711760&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84901711760&partnerID=8YFLogxK
U2 - 10.3324/haematol.2013.103218
DO - 10.3324/haematol.2013.103218
M3 - Article
C2 - 24658820
AN - SCOPUS:84901711760
VL - 99
SP - 1107
EP - 1113
JO - Haematologica
JF - Haematologica
SN - 0390-6078
IS - 6
ER -